Pascal Soriot

New test may turn AZ`s Lynparza into precision drug for prostate cancer

New test may turn AZ`s Lynparza into precision drug for prostate cancer

Published 18/06/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014. REUTERS/Stefan Wermuth/File Photo

Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

[more…]

AstraZeneca ovarian cancer drug slows disease markedly in study

AstraZeneca ovarian cancer drug slows disease markedly in study

Published 14/03/2017

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble

AstraZeneca's ovarian cancer drug Lynparza slashed the risk of disease progression in a closely watched clinical trial, boosting its profile against rivals within the novel PARP inhibitor drug class.

[more…]